Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability

被引:1
|
作者
Barr, Gordon A. [1 ,2 ,3 ]
Schmidt, Heath D. [4 ,5 ]
Thakrar, Ashish P. [6 ,7 ]
Kranzler, Henry R. [5 ,8 ]
Liu, Renyu [2 ,9 ]
机构
[1] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Anesthesiol & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[5] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA
[7] Univ Penn, Penn Ctr Addict Med & Policy, Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Crescenz VAMC, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA
[9] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
关键词
biased mu-opioid ligand; dependence; dezocine; drug discrimination; drug self-administration; opioid use disorder; RESPIRATORY DEPRESSION; CELLS;
D O I
10.1111/cns.70034
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Aims: Opioid use disorder (OUD) remains a serious public health problem. Opioid maintenance treatment is effective but under-utilized, hard to access under existing federal regulations, and, once patients achieve OUD stability, challenging to discontinue. Fewer than 2% of persons with OUD stop using opioids completely. There have been calls from public advocacy groups, governmental agencies, and public health officials for new treatments for OUD. Dezocine, a non-scheduled opioid previously used in the United States and currently widely prescribed in China for pain management, could be a candidate for a novel OUD treatment medication in the U.S. Nonetheless, to date, there have been no reviews of the clinical and preclinical literature detailing dezocine's abuse potential, a key consideration in assessing its clinical utility. Discussion: There are no English language reports of human abuse, dependence, or overdose of dezocine, despite years of extensive clinical use. There are a few case reports of dezocine abuse in the Chinese literature, but there are no reports of overdose deaths. Dezocine is perceived as an opioid and is "liked" by opioid-experienced human and non-human primates, properties that are not dose-dependent and are mitigated by ceiling effects-higher doses do not result in more "liking." There is little withdrawal, spontaneous or precipitated, in humans, monkeys, rats, or mice treated chronically with dezocine alone. However, at some doses, dezocine can precipitate withdrawal in humans and monkeys dependent on other opioids. In rodents, dezocine reduces the severity of morphine withdrawal and the rewarding properties of other opioids. Conclusions: Although dezocine is reinforcing in humans and monkeys with prior or concurrent opioid use within a restricted dose range, there are only a few anecdotal reports of dezocine abuse despite of the long history of use in humans. Given the evidence of dezocine's limited abuse potential, it could be useful both as a treatment for OUD. However, in-depth studies would be required for dezocine to be re-considered for clinical use.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Ketamine abuse potential and use disorder
    Liu, Yu
    Lin, Deyong
    Wu, Boliang
    Zhou, Wenhua
    BRAIN RESEARCH BULLETIN, 2016, 126 : 68 - 73
  • [22] Treatment of Refractory Opioid Use DisorderComparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: A Narrative Review
    Simeon Kimmel
    Paxton Bach
    Alexander Y. Walley
    Journal of General Internal Medicine, 2021, 36 : 1793 - 1793
  • [23] Relative abuse liability of opioid dosage forms in Canada: Assessing the potential for tampering
    Hard, ML
    Schuller, R
    Horbay, GLA
    Sellers, EM
    DRUG AND ALCOHOL DEPENDENCE, 2006, 83 : S84 - S84
  • [24] Artificial intelligence and opioid use: a narrative review
    Gadhia, Seema
    Richards, Georgia C.
    Marriott, Tracey
    Rose, James
    BMJ INNOVATIONS, 2023, 9 (02) : 78 - 96
  • [25] A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder
    Clark, Ashton E.
    Goodwin, Shelby R.
    Marks, Russell M.
    Belcher, Annabelle M.
    Heinlein, Emily
    Bennett, Melanie E.
    Roche, Daniel J. O.
    JOURNAL OF DUAL DIAGNOSIS, 2021, 17 (04) : 313 - 332
  • [26] Opioid use, misuse, and abuse: a narrative review about interventions to reduce opioid consumption and related adverse events in the perioperative setting
    Kim, Daniel D.
    Ramirez, Maria F.
    Cata, Juan P.
    MINERVA ANESTESIOLOGICA, 2022, 88 (04) : 300 - 307
  • [27] USE OF INVIVO APPARENT PA(2) ANALYSIS IN ASSESSMENT OF OPIOID ABUSE LIABILITY
    WOODS, JH
    WINGER, G
    FRANCE, CP
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (07) : 282 - 286
  • [28] Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review
    Kimmel, Simeon
    Bach, Paxton
    Walley, Alexander Y.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (08) : 2418 - 2426
  • [29] Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review
    Simeon Kimmel
    Paxton Bach
    Alexander Y. Walley
    Journal of General Internal Medicine, 2020, 35 : 2418 - 2426
  • [30] Case Report: Concurrent Clonidine Abuse and Opioid Use Disorder
    Mitchell, Brian G.
    Lee, Jaekyu
    JOURNAL OF PSYCHOACTIVE DRUGS, 2021, 53 (04) : 373 - 377